Acumen Pharmaceuticals, Inc.
ABOS
$-0.06
Change (1 day)
$5.09
Year High
$2.08
Year Low
Categories
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Acumen Pharmaceuticals, Inc. (ABOS) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 225 K | -38,399,000 | 43.15 M | 310.13 M | 246.62 M |
| 2022 | -129,996,000 | 7.81 M | 196.59 M | 180.33 M | |
| 2021 | -122,162,000 | 5.15 M | 230.33 M | 198.66 M | |
| 2020 | 109 K | -43,777,000 | 63.02 M | 44.43 M | 44.43 M |
| 2019 | 30 K | -6,552,000 | 18.74 M | 7.32 M | 7.18 M |